Testicular seminoma clinical stage 1: treatment outcome on a routine care level

• DOI: 10.1007/s00432-016-2162-z
• Publication Date: 2016-04-26T01:23:03Z
• Authors: Klaus-Peter Dieck...; Inken Dralle-Filiz; Cord Matthies; Julia Heinzelbecker; Jens Bedke; Jörg Ellinger; Petra Anheuser; Rainer Souchon; Uwe Pichlmeier
• Keywords: Carboplatin

Clinical stage 1 (CS1) testicular seminoma involves an almost 100 % disease-specific survival in controlled clinical trials. We aimed to find out whether these results can be matched patients managed on the routine care level.In total, 725 with CS1 were prospectively enrolled from 130 institutions. Adjuvant management as decided by local physicians involved surveillance (n = 256), radiotherapy (41), 1× Carboplatin (362), and 2× (66). registered type of management, age, duration follow-up (F/U), relapse, rete testis invasion (RTI), tumor size. Actuarial relapse-free curves calculated for treatment modalities stratified sizes RTI. A Cox regression model was explore factors influencing relapses.Disease-specific %. Crude relapse rates 8.2, 2.4, 5.0, 1.5 surveillance, radiotherapy, Carboplatin, after a median F/U 30 months. RTI size not associated progression patients. One course caused relapses 6.8 >4 cm 9.3 (actuarial 13 %) >5 cm. The revealed association recurrence entire population (Hazard ratio 1.17; 95 confidence intervals 1.03-1.33).The overall outcome level mirrors that Unexpectedly, risk confirmed, but proved indicator group seminoma. Importantly, one low efficacy control disease large tumors.